Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I believe the HIV BLA priority has dropped a bit.

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155188
(Total Views: 476)
Posted On: 06/11/2022 10:40:11 AM
Avatar
Posted By: Goosebumps
Re: I_luv_cydy #124577
I believe the HIV BLA priority has dropped a bit. I remember Nader saying the value of the HIV market as much as 8-11 billion for both combo and mono just a little over 2 years ago. Then this past fall Nader said the value is now around 30 million in market value. This is a huge drop from what we thought we had in value. There has been a lot of drugs approved for HIV in the past two year and our market value has diminished a whole bunch according to what Nader stated in a CC. This is more than likely the reason and why the priority level has dropped for HIV. All though the first approval no matter what it is… is huge. It should still be completed asap.

It doesn’t mean that a drug with no known adverse side effects and a great safety record ( we still hope) can’t be marketed to take a bigger share especially in mono but as it stands now. Especially when NAFLD benefits could benefit the people that need it most that actually have HIV. Who if I remember right had 60% chance of NAFLD/NASH problems. This is a huge selling point when your side effect is a huge benefit.

The problem is… I believe it has to be used as a third option drug and don’t understand why we bargained such a bad deal or even why deals are made where you can’t use any drug of choice when a doctor decides it’s a better choice for whatever reason. Seems like a beat down to be listed as a third choice drug and only keeps inferior drugs on the market is would seem. I just don’t understand the reasoning behind a third option drug that could out class the other two before it. These restrictions of use blow me away and if someone has a better grip on how this happens or why. Please share your opinion. It just doesn’t seem right when Leronlimab has no issues to restrict it to a 3 option drug for HIV.


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us